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Abstract. 
 
Pelizaeus-Merzbacher disease
 
 
 
(PMD) is a 
dysmyelinating disease resulting from mutations, dele-
tions, or duplications of the proteolipid protein (
 
PLP
 
) 
gene. Distinguishing features of PMD include pleio-
tropy and a range of disease severities among patients. 
Previously, we demonstrated that, when expressed in 
transfected fibroblasts, many naturally occurring mu-
tant 
 
PLP
 
 alleles encode proteins that accumulate in the 
endoplasmic reticulum and are not transported to the 
cell surface. In the present communication, we show 
that oligodendrocytes in an animal model of PMD, the 
 
msd
 
 mouse, accumulate 
 
Plp
 
 gene products in the peri-
nuclear region and are unable to transport them to the 
cell surface. Another important aspect of disease in 
 
msd
 
 mice is oligodendrocyte cell death, which is in-
creased by two- to threefold. We demonstrate in 
 
msd
 
 
mice that this death occurs by apoptosis and show that 
at the time oligodendrocytes die, they have differenti-
ated, extended processes that frequently contact axons 
and are expressing myelin structural proteins. Finally, 
we define a hypothesis that accounts for pathogenesis 
in most PMD patients and animal models of this dis-
ease and, moreover, can be used to develop potential 
therapeutic strategies for ameliorating the disease phe-
notype.
 
P
 
elizaeus-merzbacher
 
 disease (PMD)
 
1
 
 is an
X-linked leukodystrophy (McKusick, 1994) prima-
rily associated with the duplication, deletion, or mu-
tation of the proteolipid protein locus (
 
PLP
 
), and a con-
nection to several other diseases with overlapping clinical
profiles has recently become apparent from extensive ge-
netic screening (Hodes et al., 1993; Boespflug-Tanguy et
al., 1994; Kobayashi et al., 1994; Cambi et al., 1996). Yet
despite these advances, there has been little progress in
defining and characterizing the molecular mechanisms un-
derlying pathogenesis. From our analyses of PLP trafficking
in transfected fibroblasts (Gow et al., 1994
 
a
 
,
 
b
 
; Gow and
Lazzarini, 1996; Tosic et al., 1996, 1997), we have devel-
oped a hypothesis that posits that the principal effect of
many mutations in the coding region of 
 
PLP
 
 is to disrupt
the higher-ordered structure of the resulting protein iso-
forms, DM-20 and PLP, causing their accumulation in the
ER of oligodendrocytes and ultimately leading to the di-
minished biosynthetic capacity or survival of these cells.
This accumulation can be substantial since PLP mRNA
constitutes 10% of the total mRNA in myelinating oligo-
dendrocytes (Milner et al., 1985), a level that is 100 times
greater than the average abundant message. Here, we pro-
vide in vivo evidence to further support this hypothesis,
which we have broadened to account for the majority of
phenotypes in transgenic mice, 
 
Plp
 
 mutant mice, and pa-
tients with X-linked PMD.
Previous studies have reported dramatic reductions in
the number of mature oligodendrocytes in biopsies from
patients with PMD (Watanabe et al., 1973; Koeppen,
1992) and in several animal models of this disease, includ-
ing 
 
jimpy
 
 and 
 
msd
 
 mice (Skoff and Knapp, 1992). More-
over, the absence of these cells may be a major factor con-
tributing to the severe disease phenotype (Schneider et al.,
1992). A point mutation that inactivates the splice-accep-
tor site of exon 5 in 
 
jimpy
 
 mice results in a dramatic alter-
ation to the primary structure of the 
 
PLP
 
 gene products
with the absence of exon 5–encoded amino acids and a
concomitant shift in the reading frame in exons 6 and 7.
On the other hand, the missense mutation in 
 
msd
 
 mice
causes a conservative substitution of valine for alanine at
amino acid 242 of PLP (A242V). In considering these al-
leles, it is surprising that the disease phenotypes for 
 
jimpy
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: CNS, central nervous system; DAPI,
4
 
9
 
,6-diamidino-2-phenylindole; MBP, myelin basic protein; PDGF
 
a
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platelet derived growth factor 
 
a
 
–receptor; PLP, proteolipid protein;
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and 
 
msd
 
 are virtually indistinguishable (Skoff and Knapp,
1992), although we cannot rule out the possibility that sub-
tle differences in pathogenesis may exist. In detailed elec-
tron microscopic and light microscopic investigations of
cellular pathology in the central nervous system (CNS) of
 
jimpy
 
 mice, a model for severe PMD, Knapp et al. (1986)
have convincingly demonstrated that oligodendrocytes are
the principal cell type that degenerate in white matter
tracts, although apoptosis was ruled out as the mode of cell
death. More recent studies have yielded mixed conclu-
sions; increased levels of apoptotic oligodendrocyte death
is absent (Owen and Skoff, 1995; Williams and Gard,
1995) or a feature of (Skoff, 1995) pathogenesis in the
CNS of 
 
jimpy
 
 mice. Two missense alleles causing relatively
mild forms of disease have been characterized in the 
 
rsh
 
mouse (I186T) and the 
 
pt
 
 rabbit (H36Q), where oligoden-
drocyte death does not appear to be elevated above con-
trols, and the mutants have a normal life span (Taraszew-
ska and Zelman, 1987; Fanarraga et al., 1992, 1993;
Schneider et al., 1992). In addition to 
 
PLP
 
 coding region
mutations, overexpression of the wild-type 
 
Plp
 
 gene (Ka-
gawa et al., 1994; Readhead et al., 1994) or a cDNA en-
coding DM-20 in transgenic mice (Mastronardi et al., 1993;
Nadon et al., 1994; Johnson et al., 1995) is associated with
hypomyelination, and the severity of disease is propor-
tional to the level of overexpression (Ikenaka and Ka-
gawa, 1995). Partial X chromosomal duplications encom-
passing the 
 
PLP
 
 locus also give rise to PMD (for review
see Hodes and Dlouhy, 1996) and may account for a sub-
stantial proportion of patients that do not harbor coding
region mutations (Carango et al., 1995; Harding et al.,
1995; Inoue et al., 1996
 
a
 
). Finally, the minimal behavioral
phenotype in mice with targeted disruptions of the 
 
Plp
 
gene apparently in the absence of significant compensa-
tion by other gene products (Boison and Stoffel, 1994;
Rosenbluth et al., 1996; Klugmann et al., 1997) indicates
that the hypomyelinating phenotypes observed in 
 
jimpy
 
and 
 
msd
 
 mice, as well as other allelic mutants, do not re-
sult from the loss of a functional protein. In man, complete
deletions of the 
 
PLP
 
 gene or mutations that generate in-
frame stop codons near the initiating methionine give rise
to clinical disease, albeit generally a less severe form when
compared with patients with duplications or coding region
mutations (Hodes et al., 1993; Garbern et al., 1997). 
In this report, we have characterized oligodendrocyte
cell death in the CNS of 
 
jimpy
 
 and 
 
msd
 
 mice, and we have
shown biochemically and histologically using terminal
transferase labeling of fragmented DNA that apoptosis in
white matter tracts of these mutants is increased several-
fold compared with normal littermates. In addition, we
demonstrate using five oligodendrocyte-specific antibody
markers that the majority of cells undergoing apoptosis in
white matter tracts are mature oligodendrocytes that have
extended cellular processes and engaged nearby axons,
and we show by in situ hybridization that abundant DM-
20/PLP–positive oligodendrocytes are present in the brains
of 
 
msd
 
 mice. Furthermore, we show that despite the dra-
matic differences in disease severity between 
 
msd
 
 and 
 
rsh
 
mice, DM-20/PLP are largely confined to the perinuclear
region of oligodendrocytes in the brains of both of these
mutants. Thus, the in vivo immunocytochemical results
are entirely consistent with our hypothesis that mutant
 
PLP
 
 gene products misfold and accumulate in the ER
(Gow et al., 1994
 
b
 
; Gow and Lazzarini, 1996; Gow et al.,
1997). These data were presented in part at the American
Neurochemistry Society annual meeting (Gow et al.,
1995).
 
Materials and Methods
 
Purification of Genomic DNA
 
Optic nerves and sections of trigeminal nerves were rapidly dissected from
p18 
 
jimpy
 
, 
 
msd
 
, and wild-type mice and frozen on dry ice. The tissue sam-
ples were digested overnight at 50
 
8
 
C in 200 
 
m
 
l of 50 mM Tris, pH 8.0, con-
taining 0.5% SDS, 100 mM EDTA, and 240 
 
m
 
g/ml proteinase K (Sigma
Chemical Co., St. Louis, MO) and then extracted with phenol/chloroform
(1:1 by volume), pH 8.0. Finally, the genomic DNA was precipitated with
sodium acetate/ethanol and redissolved in 20 
 
m
 
l of TE. To identify 
 
msd
 
/Y
male and 
 
msd
 
/X carrier female mice of all ages by genotyping, 3–5-mm
tail tips were digested overnight at 55
 
8
 
C in 100 
 
m
 
l of TE buffer, pH 8, con-
taining 0.1% Triton X-100 and 100 
 
m
 
g/ml proteinase K and boiled for 10
min. 1 or 2 
 
m
 
l of each digest was amplified in 50 
 
m
 
l PCRs containing 50 ng
each of sense-PLP (5
 
9
 
-TTGTG CTTGC TTTTC TGTTC TAAGA
AATAA-3
 
9
 
) and antisense-PLP (5
 
9
 
-TTACC AGGGA AACTA GTGTG
GCCTC AGCAC-3
 
9
 
) primers for 40 cycles: 1 min at 94
 
8
 
C, 1 min at 55
 
8
 
C,
1 min at 72
 
8
 
C. Aliquots of the PCRs were restricted with 10 U of BsoFI
(New England Biolabs, Beverly, MA) for 2 h and then electrophoresed on
4% NuSieve agarose (FMC BioProducts, Rockland, ME) gels containing
ethidium bromide. PCR products from wild-type 
 
Plp
 
 alleles were cut into
88- and 37-bp fragments, while those from 
 
msd
 
 alleles remained intact
(125 bp). A deliberate base change (G-to-T) in the antisense primer (un-
derlined) eliminates in the PCR fragments a BsoFI site that is present in
the genomic DNA to optimize size discrimination between wild-type and
 
msd
 
 alleles on agarose gels.
 
Terminal Transferase Labeling
 
All reactions for labeling tissue sections contained terminal transferase
(TdT) at a concentration of 0.25 U/
 
m
 
l and 2.5 mM CoCl
 
2
 
 in buffer pro-
vided with the enzyme (Boehringer Mannheim Corp., Indianapolis, IN)
according to the method of Gold et al. (1993). Tetramethylrhodamine-
6-dTTP (Boehringer Mannheim Corp.) was included at a final concentra-
tion of 10 
 
m
 
M to label vibratome and cryostat sections, which were over-
laid with 30 
 
m
 
l of the reaction mixture and incubated in a humidified
chamber for 1 h at 37
 
8
 
C. Alternatively, to label genomic DNA in solution
 
z
 
1 
 
m
 
g of purified DNA (with or without prior RNase A treatment) and 50
 
m
 
Ci of [
 
a
 
-
 
32
 
P]ddATP (Amersham Corp., Arlington Heights, IL) were
added to the buffer/enzyme mixture in a total volume of 20 
 
m
 
l, and the re-
action was incubated for 1 h at 37
 
8
 
C. The labeled DNA was separated
from free nucleotides using a spin column (Stratagene, La Jolla, CA) and
precipitated with sodium acetate/ethanol/glycogen, and 5 
 
3 
 
10
 
4
 
 dpm were
loaded onto 4% NuSieve agarose gels. After electrophoresis, the DNA
samples were transferred to Nytran Plus membranes (Schleicher and
Schuell, Inc., Keene, NH) using a standard Southern blotting protocol
(Sambrook et al., 1989) and exposed to x-ray film at 
 
2
 
80
 
8
 
C.
 
Immunocytochemistry
 
Mice were anesthetized with tribromoethanol and fixed by vascular perfu-
sion with 100 ml of freshly prepared 4% paraformaldehyde in 0.1 M so-
dium phosphate, pH 7.2. Brains and spinal cords were dissected and
stored for up to 1 wk at 4
 
8
 
C in phosphate buffer. Some tissue blocks were
infiltrated with 20% sucrose in phosphate buffer at 4
 
8
 
C and embedded in
OCT for cryostat sectioning. Frozen sections (10 
 
m
 
m) were thaw-mounted
on Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA) and stored at
 
2
 
20
 
8
 
C. For labeling with the O4 and Ranscht antibodies (M. Schachner,
Eidgenössische Techische Hochschule, Zurich, Switzerland), sections re-
mained unpermeabilized until after incubation with the secondary anti-
body and fixation in 4% paraformaldehyde/phosphate buffer for 10 min.
For antibodies against myelin basic protein (MBP) (130–137; Boehringer
Mannheim Corp.; No. 644, D.R. Colman, Mount Sinai School of Medi-
cine), DM-20/PLP (AA3 [Yamamura et al., 1991]), platelet-derived
growth factor 
 
a
 
–receptor (PDGF
 
a
 
R) (Upstate Biotechnology, Inc., Lake
Placid, NY; R7, C. Heldin, Ludwig Institute, Uppsala, Sweden), neurofila- 
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ments (2H3 [Guthrie and Pini, 1995], Developmental Hybridoma Bank,
University of Iowa, Iowa City, IA; SMI31/32, Sternberger Monoclonals,
Inc., MD), and histones (MAB052, Chemicon International, Temecula,
CA), the sections were permeabilized for 15 min in methanol and then in-
cubated for 30 min in blocking solution (Gow et al., 1994
 
a
 
). The sections
were incubated in primary antibodies at room temperature for 2 d or over-
night, and subsequent antibody steps were for 3 h duration. Intervening
wash steps were carried out for 2
 
3
 
 10 min in TBS. Finally, the sections
were incubated in 2 
 
m
 
g/ml 4
 
9
 
,6-diamidino-2-phenylindole (DAPI) to stain
nuclei and mounted in 2.5% 1,4-diazabicyclo-(2,2,2)-octane (DABCO)
(Sigma Chemical Co.) and 50 mM Tris, pH 8.6, in 90% glycerol (Johnson
et al., 1982). Alternatively, 50-
 
m
 
m vibratome sections of transverse spinal
cord were cut and then processed while free-floating. These sections were
permeabilized in TBS containing 0.5% Triton X-100 before being labeled
with antibodies using the same protocol described for cryostat sections. 
 
In Situ Hybridization
 
Digoxigenin-labeled sense and antisense RNA probes were synthesized
by in vitro transcription (Genius 4 labeling kit; Boehringer Mannheim
Corp.) of a linearized plasmid comprising a 1.4-kb EcoRI human PLP
cDNA (Puckett et al., 1987) in pBS using T3 or T7 RNA polymerases.
The probes were not hydrolyzed, and their concentrations were deter-
mined after agarose/formaldehyde electrophoresis and Northern blotting
using anti–digoxigenin-alkaline phosphatase (Genius 3 detection kit) by
comparison of signal intensities with known digoxigenin-labeled stan-
dards. 10-
 
m
 
m cryostat sections were permeabilized in 0.1% Triton X-100/
TBS for 30 min and overlaid with 25 
 
m
 
l of a hybridization solution (Strable
et al., 1994) containing 50% formamide, 2
 
3
 
 sodium chloride/sodium phos-
phate/ethylmaleimide-tetra-acetate (SSPE), 10% dextran-sulfate, 1
 
3
 
Denhardt’s (Sambrook et al., 1989), and 1 mg/ml tRNA and prehybrid-
ized for 2 h at 55
 
8
 
C under a parafilm “coverslip.” Probes were boiled for 5
min and added to fresh prehybridization solution at a final concentration
of 0.2 ng/
 
m
 
l, overlaid onto the sections, and coverslipped for overnight hy-
bridization at 55
 
8
 
C. Thereafter, the slides were washed 2
 
3
 
 30 min at 65
 
8
 
C
in 5
 
3
 
 SSPE/50% formamide, 2
 
3
 
 30 min at 65
 
8
 
C in 1
 
3
 
 SSPE/25% forma-
mide/0.5
 
3
 
 PBS, and finally at 25
 
8
 
C in 0.1% Tween-20/PBS for 30 min.
Sections were processed for alkaline phosphatase immunohistochemistry
using the Genius 3 detection kit. The enzyme reactions with NBT/BCIP
were carried out at 20
 
8
 
C for 
 
z
 
2 h on wild-type sections and 20 h on 
 
jimpy
 
and 
 
msd
 
 sections.
 
Results
 
Elevated Levels of Apoptosis in jimpy and msd Mice
 
Studies by many investigators over the last few years have
established that cell death can occur by at least two dis-
tinct mechanisms: necrosis, which is often the result of
physical tissue damage, and apoptosis, which can be initi-
ated by a variety of noxious stimuli. Three analytical tech-
niques have been used to identify cells undergoing apopto-
sis in vivo. Electron microscopy reveals the condensation
of chromatin along the inner nuclear membrane, while cy-
toplasmic organelles remain relatively unaffected in apop-
totic cells. Gel electrophoresis of DNA from apoptotic
cells reveals a characteristic fragmentation into small seg-
ments that are multiples of 180 bp. This DNA fragmenta-
tion is exploited in the third method of analysis, terminal
transferase (TdT) labeling of the fragments with labeled
deoxynucleotide triphosphates. 
Previous studies (Barres et al., 1992) have showed that a
low level of oligodendrocyte apoptosis occurs normally in
developing brain. This level of cell death is reflected as a
faint 180-bp ladder in the electrophoretogram of DNA
from the optic nerves of a wild-type mouse (Fig. 1, 
 
second
lane
 
). The intensity of the DNA ladder obtained with
DNA from the optic nerve of 
 
jimpy
 
 mice (
 
fourth lane
 
),
however, is several-fold more intense. The amounts of the
high molecular weight DNA in the second and fourth
lanes are similar, indicating that similar amounts of DNA
for both samples were loaded onto the gel and that the
greater intensity of the lower bands in 
 
jimpy
 
 mice results
from an increase in DNA fragmentation. Prominent DNA
ladders from the optic nerves of 
 
msd mice (data not
shown) are indistinguishable from that shown for jimpy
optic nerve. In contrast to CNS, the level of apoptosis in
peripheral nervous system trigeminal nerves (Fig. 1, Trig.)
of wild-type and jimpy mice is not detectable (third and
fifth lanes). These lanes are included as controls, showing
that the laddering is not a product of our DNA isolation
procedure.
Transverse sections of thoracic spinal cord from p18
wild-type,  jimpy, and msd mice show terminal transferase
labeling with a fluorescent substrate (Fig. 2, red) in the re-
gion of the lateral ventral white matter tracts (Fig. 2, a–c).
While labeled nuclei are present in wild-type tissue, they
are much more abundant in jimpy and msd tissue, consis-
tent with the data in Fig. 1. The condensation of chromatin
is apparent in two terminal transferase–labeled nuclei
from  msd spinal cord shown at high power (Fig. 2 d). Mar-
gination of the chromatin in four foci along the inner nu-
clear membrane is visible in the nucleus on the right as
shown by a DAPI stain of the same field (Fig. 2 e). The nu-
clei not labeled by terminal transferase in Fig. 2 d have a
normal appearance and stain relatively evenly with DAPI.
The transverse spinal cord sections in Fig. 2, a–c, are coun-
terstained (green) with an antiserum against MBP that re-
veals many heavily myelinated axons as bright rings of flu-
orescence in wild-type specimens (Fig. 2 a). Sections from
the mutant mice (Fig. 2, b and c) are also stained, albeit at
dramatically reduced levels, where oligodendrocyte-derived
MBP-positive membranes have enveloped some axons.
Figure 1. Autoradiogram showing terminal transferase–labeling
of 180-bp DNA ladders in optic nerve (Opt.) samples from p18
wild-type (second lane) and jimpy (fourth lane) mice. DNA lad-
ders are not detectable in trigeminal nerve (Trig.) samples (third
and fifth lanes). A radiolabeled 123-bp ladder (first lane) was
used to calculate Mr of DNA fragments in the tissue samples.The Journal of Cell Biology, Volume 140, 1998 928
This feature is most obvious in Fig. 2 b, where the oblique
plane of the section clearly demonstrates that oligoden-
drocytes in these animals are able to fully differentiate,
contact nearby axons, and synthesize myelin membrane
components. 
Using the terminal transferase detection of apoptotic
cells, coupled with DAPI staining to independently assess
the condensation of chromatin and abnormal appearance
of the nuclei, we quantified cell death in cryostat sections
from four regions in the spinal cords of 10-d-old (p10) msd
mice and wild-type male littermates (Table I). Counts
were obtained for 4–12 transverse serial sections from
each of the cervical, thoracic, lumbar, and sacral regions,
and these data show that apoptosis is increased by two- to
threefold along the length of the spinal cords of msd mice
compared with littermate controls. These results accord
with the elevated levels of cell death quantified in the cer-
vical spinal cords of jimpy mice, which were found to be
2.7- and 4.8-fold above that in wild-type littermates at ages
p7 and p12, respectively (Knapp et al., 1986). Surprisingly,
the absolute numbers of degenerating cells reported for
cervical spinal cord in that study, which were identified on
the basis of morphological changes in 1-mm plastic sec-
tions, are z10-fold greater than our data for an equivalent
thickness of section. While a portion of this difference
likely reflects the greater severity of disease caused by the
jimpy mutation compared with msd and differences in ge-
netic background between the two alleles, we surmise that
the TdT assay detects cells in the final stages of degenera-
tion at a point when the cellular dissolution may well be
proceeding at its maximal rate. On the other hand, the
early morphological changes catalogued by Knapp et al.
(1986) may proceed at a slow rate, thereby rendering indi-
vidual degenerating cells visible for a greater length of
time. 
Mature Oligodendrocytes Undergo Apoptosis in
msd Mice
Previous electron microscopic analyses of degenerating
cells in jimpy mouse CNS identified oligodendrocytes by
characteristic morphological criteria (Knapp et al., 1986);
however, the stage in the oligodendrocyte lineage that
these cells had attained was not easily discernible. Thus, to
assess the degree to which oligodendrocytes of the mutant
animals differentiate before they undergo apoptosis, we
double labeled parasagittal sections from msd mice using
terminal transferase (Fig. 3, red) and antibodies to several
oligodendrocyte-specific markers (green): O4, which is
synthesized by progenitor cells as well as mature oligoden-
drocytes (Fig. 3 a); Ranscht antigen, which is synthesized
by postmitotic and mature oligodendrocytes (Fig. 3 b); and
DM-20/PLP and MBP, which are synthesized by mature
myelinating oligodendrocytes (Fig. 3, c and d, respec-
tively). Apoptotic nuclei are shown in Fig. 3 a labeled with
O4 antibody and in Fig. 3 b labeled with Ranscht antibody.
A considerable amount of myelin-like membrane debris is
apparent in these micrographs that presumably resulted
from oligodendrocyte degeneration. The presence of DM-
20/PLP–positive membrane surrounding many apoptotic
nuclei (Fig. 3 c) indicates that oligodendrocytes in the mu-
Figure 2. Immunofluores-
cence images of lateral ventral
spinal cord white matter tracts
in transverse sections from
p18 wild-type (a), msd ( b ),
and  jimpy ( c ) mice. MBP-
positive membrane (green)
surrounds a few axons in the
mutants and terminal trans-
ferase–labeled nuclei (red)
are present in all three sec-
tions. (d) High magnification
of two terminal transferase–
labeled nuclei in a longitudi-
nal section of spinal cord
from an msd mouse. Many
normal-appearing nuclei are
present in this field and are
revealed by the DAPI stain
(e). The terminal transferase
reaction product colocalizes
with the DAPI staining of
the condensed marginated
chromatin. Bars: (a–c) 50
mm; (d and e) 10 mm.
Table I. Quantitation of Apoptotic Nuclei in the Spinal Cords of 
Wild-Type and msd Mice*
Region Wild-type msd
Ratio
(msd/wt)
Cervical 12.8 6 2.0 43.9 6 5.9 3.4
Thoracic 9.4 6 0.3 24.5 6 1.5 2.6
Lumbar 9.7 6 1.4 22.2 6 2.1 2.3
Sacral 6.4 6 0.3 10.6 6 2.6 1.7
*Apoptotic nuclei were counted in 4–12 serial transverse sections in each region of
spinal cord from all animals at age p10. The data are presented as mean 6 SEM from
three wild-type and two msd mice.Gow et al. DM-20/PLP Trafficking in msd and rsh Mice 929
tant animals fully differentiate to the point at which they
are synthesizing myelin membrane components. Fig. 3 d
shows an MBP-positive oligodendrocyte at high power
with several processes extending away from the cell body.
Condensed, marginated chromatin in the nucleus of this
cell is clearly revealed by the terminal transferase labeling
(red). Together, these data substantiate the view that oli-
godendrocytes differentiate and begin to synthesize mye-
lin membrane components before they undergo apoptosis. 
The proportions of TdT-positive apoptotic cells that
were labeled with one of five oligodendrocyte-specific
markers were quantified in the hypothalamus, pons, me-
dulla, and cervical spinal cords of msd mice (Table II).
Several studies have shown that the expression of these
markers, once initiated, is maintained during subsequent
stages of cellular differentiation through to myelinating
oligodendrocytes with the exception of PDGFaR. The
gene encoding this protein is expressed in O-2A progeni-
tor cells but downregulated in immature oligodendrocytes
before the appearance of mature markers such as MBP
and PLP by immunocytochemistry (Ellison and de Vellis,
1994; Nishiyama et al., 1996). Approximately 75% of apop-
totic cells in the msd mice are stained with antibodies
against DM-20/PLP, a percentage that is corroborated by
the O4 and Ranscht antigen markers, each of which stain
83% of apoptotic cells. On the other hand, we found that
only a small proportion of TdT-labeled cells were also la-
beled by either of two independently derived polyclonal
antibodies directed against PDGFaR. Although we can-
not rule out the possibility that epitopes on the PDGFaR
are unstable or masked in apoptotic cells, the results ob-
tained for this antigen are consistent with the DM-20/PLP
data. Reasons for the comparatively low proportion of
MBP-positive apoptotic nuclei are not certain; however,
MBP is a soluble protein that is normally very susceptible
to attack by proteases, and our data may reflect the insta-
bility of the antibody epitope in apoptotic cells. Finally, if
we assume that the O4 antibody is able to detect essen-
tially all of the oligodendrocyte lineage cells that undergo
apoptosis in msd mice, then our data show that 90 6 5% of
those cells are mature oligodendrocytes. 
Abundant DM-20/PLP mRNA–positive 
Oligodendrocytes in msd Mice
While the majority of apoptotic nuclei are surrounded by
membrane that is strongly DM-20/PLP–positive, the mi-
crographs in Fig. 3 do not impart any appreciation for the
number of viable oligodendrocytes in the CNS of mutant
animals. To this end, we performed in situ hybridization
on parasagittal sections of brain from p18 wild-type and
msd mice using a digoxigenin-labeled PLP cRNA probe.
In Fig. 4 a, the corpus callosum (cc) and subcortical white
matter tract extending to the right are heavily populated
by DM-20/PLP–positive oligodendrocytes and many ma-
ture oligodendrocytes also line the periventricular zone. In
Fig. 4 b, DM-20/PLP–positive oligodendrocytes are present
in the same regions of white matter as for the wild-type an-
imal, again supporting the notion that many msd oligoden-
drocytes fully differentiate and express genes encoding
myelin-specific proteins before degenerating. Similar re-
sults were obtained for jimpy mice. The development
times for alkaline phosphatase histochemistry were 5–10
times longer for sections from the mutants than for con-
trols suggesting that the levels of DM-20/PLP mRNA in
msd oligodendrocytes is lower than in wild-type cells. 
DM-20/PLP Remain Perinuclear in msd and rsh
Mouse Oligodendrocytes
With the strong indication that the majority of oligoden-
drocytes in jimpy and msd mice express myelin-specific
proteins at the time they undergo apoptosis (Figs. 2–4; Ta-
ble II), we investigated the intracellular distributions of
two of these proteins, MBP and PLP. Immunofluores-
cence staining of spinal cords from the mutant animals
(Fig. 2) shows that oligodendrocyte processes recognize
and envelop axons with MBP-positive membrane. On the
other hand, our hypothesis predicts that DM-20/PLP in
jimpy and msd mice should accumulate in the ER of oligo-
Figure 3. Immunofluorescence staining of cells undergoing apop-
tosis (red) in the midbrains of p18 msd mice. These cells are
stained by antibodies to different oligodendrocyte-specific mark-
ers: O4 (a), Ranscht (b), PLP (c), and MBP (d). Bars: (a–c) 10
mm; (d) 2 mm.
Table II. Proportion (%) of Apoptotic Cells That Stain Positive 
for Oligodendrocyte-specific Markers by Immunofluorescence
Oligodendrocyte-
specific antigen
No. of
mice
No. of apoptotic
cells counted
Antigen-positive
cells (%)
PLP 3 183 75 6 0.5
O4 3 110 83 6 4
Ranscht 3 176 83 6 3
MBP 3 134 43 6 8
PDGFaR 2 353 8 6 0.5
Oligodendrocyte-specific antigen-positive/TdT-positive/DAPI-positive cells were lo-
cated in the hypothalamus, pons, medulla, and cervical spinal cord. Counts are pre-
sented as mean 6 SEM and were obtained from 10-mm sagittal cryostat sections of
brain from two or three p18 msd mice.The Journal of Cell Biology, Volume 140, 1998 930
dendrocytes. To test this prediction, we labeled sagittal
brain sections of p18 wild-type msd and rsh mice with a
monoclonal antibody raised to the carboxyl terminus of
DM-20/PLP and one of two antibodies against MBP to lo-
cate myelinating oligodendrocytes. A spatial and temporal
wave of myelination spreads through the developing CNS
with a well-defined course, and the region of the cerebral
cortex shown in Fig. 5 was chosen to illustrate an area that
is relatively sparsely myelinated. Oligodendrocyte cell
bodies in wild-type brain (Fig. 5, a–c, arrowheads) contain
both MBP (Fig. 5 a) and DM-20/PLP (Fig. 5 b). Myelina-
tion is evident in this field from the numerous axons that
have been enveloped in MBP- and DM-20/PLP–positive
membrane, thereby rendering them yellow in the overlay
(Fig. 5 c). A comparable region of cortex from an msd lit-
termate is shown in Fig. 5, d–f, and oligodendrocyte cell
bodies in this field are positive for both MBP and DM-20/
PLP (arrowheads). However, there is little evidence of
DM-20/PLP in oligodendrocyte-derived membranes sur-
rounding nearby axons. Rather, these data clearly demon-
Figure 4. In situ hybridiza-
tion in brain sections of p18
wild-type (a) and msd ( b )
mice using an antisense-PLP
cRNA probe. Adjacent sec-
tions from each animal hy-
bridized with sense-PLP
probes  were unstained. cc,
corpus callosum; hc, hippo-
campus. Bar, 100 mm.
Figure 5. Immunofluores-
cence staining for MBP (a, d,
and g) and DM-20/PLP (b, e,
and h) in p18 wild-type (a–c),
msd ( d–f), and rsh ( g–i)
mouse neocortex. In wild-
type mice, MBP and DM-20/
PLP staining are extensively
colocalized in the cell bodies
(arrowheads) as well as in
oligodendrocyte processes
that are in contact with
nearby axons (c). In msd
mice, the presence of oligo-
dendrocyte processes wrapped
around axons is inferred
from the MBP staining (d),
which has a similar morphol-
ogy to that in wild-type mice
(a). However, DM-20/PLP
staining is limited to the peri-
nuclear region of oligoden-
drocytes, suggesting that the
intracellular trafficking of
this mutant protein is dis-
rupted (e). In rsh mice, the
trafficking of DM-20/PLP (h)
is disrupted in a similar fash-
ion to msd mice (e) except
that low levels of DM-20/
PLP are visible in myelin
sheaths. Bar, 20 mm.Gow et al. DM-20/PLP Trafficking in msd and rsh Mice 931
strate that mutant Plp gene products are essentially con-
fined to the perinuclear region of oligodendrocytes. The
fact that msd oligodendrocytes are able to extend pro-
cesses that contact and invest axons is evident from the
MBP staining surrounding axons (Fig. 5 d ) in a similar
fashion to that in wild-type cortex (Fig. 5 a). 
In contrast to the severe dysmyelination in the CNS of
msd mice, which live only 3–4 weeks after birth, the dis-
ease in rsh mice on the same genetic background is rela-
tively mild and is characterized by hypomyelination. Fur-
thermore, hemizygous males and females homozygous for
the rsh allele can breed and have a normal life span. None-
theless, the intracellular trafficking defect revealed for
DM-20/PLP in msd mice is also apparent in oligodendro-
cytes in the cortex of p21 rsh mice (Fig. 5, g–i). Similar to
the immunofluorescence staining for msd mice, oligoden-
drocytes in rsh mice invest nearby axons in MBP-positive
membrane (Fig. 5 g). However, the majority of the myelin
sheaths have low levels of DM-20/PLP staining despite the
tremendous amount of these proteins in the perinuclear
region of oligodendrocytes (Fig. 5 h, arrowheads). Thus,
these data are consistent with previous immunoelectron
microscopic studies in jimpy mice (Roussel et al., 1987)
and strongly support our hypothesis (Gow et al., 1994a,b;
Gow and Lazzarini, 1996; Gow et al., 1997) that many mis-
sense PLP mutations cause the encoded gene products to
accumulate in the ER. This accumulation probably stems
from misfolding of the mutant proteins, a notion which is
consistent with our immunocytochemical data in trans-
fected cells using three conformationally sensitive anti–
DM-20/PLP antibodies, 1A9 and O10 (Gow et al., 1997)
and 81-11 (unpublished data).
An exciting aspect of the data in Fig. 5 is the differential
effect of the rsh allele on the intracellular trafficking of the
mutant DM-20/PLP proteins. Previous immunocytochemi-
cal investigations of rsh CNS with PLP-specific antibodies
indicated that this isoform (i.e., PLPrsh) is present at low
concentrations in myelin sheaths (Fanarraga et al., 1992).
Moreover, western blots from these mutant mice showed
that in purified myelin fractions, the amount of PLPrsh is
sharply reduced compared with littermates, while DM-
20rsh is present at levels that are close to normal (Mitchell
et al., 1992). These observations bear a striking resem-
blance to our previous analyses of the intracellular traf-
ficking of mutant DM-20/PLPs in transiently transfected
fibroblasts where DM-20rsh was found to traverse the
secretory pathway to the cell surface while PLPrsh accumu-
lated in the ER (Gow et al., 1994b; Gow and Lazzarini,
1996). We also showed that when coexpressed, DM-20rsh
mediated the trafficking of some of the PLPrsh to the cell
surface in a concentration-dependent manner, perhaps by
forming transport-competent heteromeric complexes and
thereby reducing the amount of mutant PLP in the ER.
On the other hand, the presence of DM-20msd, which by it-
self accumulates in the ER, had no effect on the intracellu-
lar localization of PLPmsd, and both proteins remained
perinuclear. The coexpression of several other mutant
DM-20/PLPs in fibroblasts yielded identical results (Gow
and Lazzarini, 1996; Tosic et al., 1997), suggesting that an
“assisted transport” mechanism may be of particular im-
portance to the pathogenesis of PMD. Thus, in the light of
previous biochemical analyses in rsh mice (Fanarraga et
al., 1992; Mitchell et al., 1992), the data shown in Fig. 5, d–i,
provide strong in vivo evidence for an inverse correlation
between the proficiency of mutant PLP gene products to
traverse the secretory pathway and the severity of disease
elicited by the mutation, as predicted from our transfec-
tion studies (Gow and Lazzarini, 1996). 
Pathogenesis in Plp-overexpressing Transgenic Mice
Transgenic mice bearing supernumerary autosomal copies
of a wild-type murine Plp gene develop a dose-dependent
(Ikenaka and Kagawa, 1995) hypomyelinating disease
with a number of similarities to msd and rsh mice. Three
independent lines of Plp-overexpresser transgenic mice,
No. 72, No. 66, and No. 4e, have been characterized (Ka-
gawa et al., 1994; Readhead et al., 1994), and each exhibits
an increase in overall DM-20/PLP expression from 1.3- to
5.2-fold above littermate controls that is further increased
in the homozygous animals to as much as 7.4-fold (Inoue
et al., 1996b). These mice develop a nonimmune-mediated
demyelinating disease, the severity of which is propor-
tional to the level of Plp overexpression (Ikenaka and Ka-
gawa, 1995). A demyelinating disease stemming from the
overexpression of DM-20 cDNA in oligodendrocytes has
also been reported (Mastronardi et al., 1993; Johnson et al.,
1995).
To determine whether the intracellular trafficking of
DM-20/PLP is disrupted in Plp-overexpresser mice in a
manner similar to that shown in Fig. 5 for the msd and rsh
mutants, we examined tissue sections from line No. 72
transgenic mice using immunocytochemistry. Fig. 6 a shows
a parasagittal section of neocortex from a 3-mo-old wild-
type mouse using an antibody raised against neurofila-
ments (red). Many radiating and longitudinal axons track-
ing along the superior surface of the corpus callosum are
ensheathed in DM-20/PLP–positive myelin (green) and are
continuous for considerable distances through the section.
Immunofluorescence staining in the neocortex of an age-
matched homozygous Plp-overexpresser (line No. 72) is
shown in Fig. 6 b. Disease in this mouse was at an ad-
vanced stage at the time of perfusion. While the neuronal
architecture in this animal appears relatively intact, the
amount of myelin revealed by DM-20/PLP staining in the
cortex is drastically reduced compared with the wild-type,
and abnormalities are apparent at the cellular level. Ar-
rowheads point to several neurofilament-rich lesions that
were observed throughout the brain as previously noted in
many myelin mutants (Seitelberger, 1970; Dentinger et al.,
1982; Rosenfeld and Freidrich, 1983; Readhead et al.,
1994). Small arrows show large swellings in myelin sheaths
that are abundant throughout the CNS of these and other
myelin mutants (Rickman, D., and R.A. Lazzarini, manu-
script in preparation; Gravel et al., 1996). DM-20/PLP–
positive oligodendrocyte cell bodies are visible in Fig. 6 b
(thick arrows); however, these cells appear to have lost
their processes. While this aspect of pathology accounts
for the paucity of myelinated axons, it precludes us from
determining whether or not the trafficking of DM-20/PLP
has been disrupted. Immunofluorescence staining of ad-
jacent brain sections with antibodies against 29,39-cyclic
nucleotide 39-phosphodiesterase, myelin-associated glyco-
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yielded staining patterns that were extensively colocalized
with the DM-20/PLP staining and confirm the lack of pro-
cesses extending from the majority of these cells (data not
shown). The inset in Fig. 6 b shows an oligodendrocyte cell
body at high magnification stained with antibodies against
DM-20/PLP (green), MBP (red), and histones (blue) to
highlight the nucleus. Previous studies have suggested that
oligodendrocytes fail to differentiate in the Plp-overex-
pressers (Kagawa et al., 1994; Readhead et al., 1994); how-
ever, our data clearly show an abundance of cells expressing
multiple markers of mature oligodendrocytes.
Discussion
The cellular and molecular defects responsible for the
pleiotrophic phenotypes of the PLP mutants have been
subjects of intense investigation. An underlying theme of
many earlier studies has been the suggestion that dysmy-
elination in the CNS of these mutants stems from an ab-
sence of functional DM-20/PLP, which arrests the differ-
entiation of virtually all oligodendrocyte progenitors at an
immature stage, resulting in the accumulation of premyeli-
nating cells that subsequently die (Webster and Stern-
berger, 1980; Skoff and Knapp, 1992; Nadon and Duncan,
1995). However, our analyses of jimpy and msd mice af-
fords an alternative explanation of pathogenesis—that
precursors differentiate into mature oligodendrocytes that
extend processes, make contact with nearby axons, and
initiate the synthesis of proteins such as MBP and PLP
(see Table II; Figs. 2–5) before undergoing apoptosis. The
presence of oligodendrocyte-derived membrane around
the axons of jimpy and msd mice (Fig. 5; Ghandour and
Skoff, 1988) and the virtual absence of compact myelin in
these mutants (Billings-Gagliardi et al., 1980) further sub-
stantiate this notion. Thus, our data strongly support a
view that the primary pathologic effect of many PLP mu-
tations is the perinuclear accumulation of mutant proteins
in mature oligodendrocytes, which frequently induces apop-
totic death. Studies by Kagawa et al. (1994) and Inoue et
al. (1996a,b) suggest that the overexpression of wild-type
PLP, if sufficiently robust, also causes a dysmyelinating
disease with a phenotype very similar to that observed in
jimpy and msd mice. Our analysis of the homozygous No.
72 Plp-overexpressers clearly indicates that mature oligo-
dendrocytes are abundant in the brain and that demyelina-
tion likely stems from an inability of these cells to main-
tain contact with and/or remyelinate nearby axons rather
than an impaired differentiation of oligodendrocyte lin-
eage cells as previously proposed (Kagawa et al., 1994;
Readhead et al., 1994).
In light of our evidence that oligodendrocyte differenti-
ation is not impaired in the Plp mutants, what kind of
mechanism might elicit disease in these animals? We hy-
pothesize that the accumulation of nascent gene products
in the secretory pathway governs the pathogenesis. If mu-
tant protein is synthesized at a slow rate, the oligodendro-
cyte can degrade the misfolded nascent polypeptides in
the ER without any lasting damage to the cell. On the
other hand, if the rate of mutant protein synthesis exceeds
the capacity of the cell to degrade it, the protein may accu-
mulate to levels that interfere with cellular function and
eventually trigger apoptosis. This concept has consider-
able merit and enables us to account for the phenotypes
observed in most patients with PMD. Our previous studies
in transfected cells (Gow et al., 1994a,b; Gow and Laz-
zarini, 1996; Tosic et al., 1996, 1997) demonstrated that
eleven disease-causing missense mutations in extracellu-
lar, transmembrane, and cytoplasmic regions cause DM-20
and/or PLP to accumulate in the ER of COS-7 cells, sug-
gesting that some form of disruption in the secretory path-
way may cause disease. This conclusion is consistent with
the immunocytochemical data in Fig. 5 showing disrupted
DM-20/PLP trafficking in the msd and rsh mice, previous
immunoelectron microscopic analyses showing that DM-
20/PLP is confined to the ER of jimpy oligodendrocytes in
vivo (Nussbaum and Roussel, 1983; Schwob et al., 1985;
Roussel et al., 1987), and by the jimpy-like phenotype that
is observed in transgenic mice (Turnley et al., 1991;
Yoshioka et al., 1991) in which the integral membrane
protein, MHC-Kb, accumulates in the ER of oligodendro-
cytes (Power et al., 1996). Furthermore, elevated expres-
sion of the gene encoding the ER luminal chaperone BiP
in the brains of jimpy and msd mice (Hudson and Nadon,
1992) is consistent with metabolic stress (Shamu et al., 1994). 
Our hypothesis also accommodates the apparent contin-
uum of disease severities observed among patients with
coding region mutations by taking into account epistatic
effects such as those that influence the pathogenesis of
Figure 6. Immunofluorescence
staining for DM-20/PLP (green)
and neurofilaments (red) in
3-mo-old wild-type (a) and No. 72
homozygous  Plp-overexpresser
mice (b) showing comparable
regions of the cerebral cortex
superior to the corpus callosum
(bottom of panels). (Inset) High-
power image showing a typical
oligodendrocyte cell body from
a No. 72 mouse stained with anti-
bodies against DM-20/PLP (green),
MBP (red), and histones (blue).
Bar, 50 mm.Gow et al. DM-20/PLP Trafficking in msd and rsh Mice 933
other diseases. For example, previous studies have shown
that the rate of degradation of mutant protein in the ER is
variable within the population and that susceptibility to
liver disease in patients harboring PiZZ mutations in the
gene encoding a1-antitrypsin is inversely correlated with
the protein degradation rate (Wu et al., 1994). Thus, for
PMD we hypothesize that some alleles at secondary sites
that slightly reduce the operating efficiency of the ER deg-
radation pathway in oligodendrocytes and other cell types
should confer a greater susceptibility to the effects of mu-
tant DM-20/PLP accumulation than others, thereby giving
rise to a spectrum of disease severities both within and be-
tween pedigrees. Other mechanisms may diminish the rate
of accumulation of mutant PLP gene products. In this re-
gard, we have previously demonstrated that facilitated
trafficking through the secretory pathway of mutant PLPs
by their cognate DM-20s is correlated with less severe
forms of disease such as classical PMD and spastic para-
plegia (Gow and Lazzarini, 1996). 
Finally, protein accumulation in the secretory pathway
may also account for disease associated with the overex-
pression of wild-type PLP gene products (Carango et al.,
1995; Inoue et al., 1996a). Although we have not estab-
lished whether DM-20/PLP accumulates in the perinuclear
region of oligodendrocytes in the No. 72 strain of Plp-
overexpressing transgenic mice, these data do not pre-
clude the possibility that disruptions to DM-20/PLP traf-
ficking may underlie pathogenesis. Kagawa et al. (1994)
and Inoue et al. (1996b) have reported that 4e homozy-
gous mice develop a robust behavioral phenotype and ex-
hibit pathological changes in the CNS that are strikingly
similar to jimpy and msd mice, including the accumulation
of DM-20/PLP in the perinuclear region of oligodendro-
cytes (Macklin et al., 1995) and markedly increased levels
of oligodendrocyte apoptosis. With regard to pathogenesis
in the No. 72 Plp-overexpressers, the perinuclear accumu-
lation of DM-20/PLP in 4e oligodendrocytes suggests that
the oligodendrocyte pathology illustrated in Fig. 6 may re-
flect a DM-20/PLP trafficking disturbance that is insufficient
to trigger apoptosis but nevertheless impairs the biosyn-
thetic capacity of oligodendrocytes and decreases their
ability to maintain their processes and myelin sheaths. This
view is consistent with a dependence of disease severity on
the level of Plp overexpression, starting with less than a
twofold increase in steady-state mRNA levels, and with
early pathological changes that have been observed in oli-
godendrocytes by electron microscopy, including disten-
tion and vesiculation of the ER and/or Golgi apparatus
(Kagawa et al., 1994; Readhead et al., 1994; Inoue et al.,
1996b). 
Apart from defining the molecular mechanism of patho-
genesis in PMD, our hypothesis makes strong predictions
about strategies that may be used to ameliorate the sever-
ity of this disease. In general, the synthesis of mutant PLP
gene products or overexpression of the wild-type gene is
of greater detriment to oligodendrocytes than the absence
of these proteins (Hodes et al., 1993; Boison and Stoffel,
1994; Sistermans et al., 1996; Garbern et al., 1997; Klug-
mann et al., 1997; Yang and Skoff, 1997), which suggests
that reducing PLP expression should benefit most PMD
patients. In this regard, antisense phosphorothioate oligo-
nucleotides have been shown to dramatically improved
the survival of jimpy oligodendrocytes in culture (Yang
and Skoff, 1997) and suggest that this strategy might also
succeed in vivo. Furthermore, our hypothesis predicts that
therapies based on gene complementation strategies
would be largely unsuccessful in most DM-20/PLP–linked
diseases because increased levels of PLP gene products
may further increase the accumulation of protein in the
ER and exacerbate pathology. Indeed, studies from three
independent groups have failed to rescue jimpy mice with
supernumerary copies of the Plp gene (Kagawa et al.,
1994; Nadon et al., 1994; Readhead et al., 1994; Schneider
et al., 1995). As shown in Fig. 6 and studies by other groups,
the overexpression of Plp transgenes in wild-type mice causes
a hypomyelinating phenotype (Kagawa et al., 1994; Read-
head et al., 1994). On the other hand, PMD patients in
which PLP is deleted, or is functionally null, may well ben-
efit from gene replacement, provided the level of transgene
expression does not exceed that of the wild-type gene.
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